Many oncologists dropping the ball at first consult, study says

The first meeting between a patient and a hematology-oncology subspecialist is a crucial event in the cancer patient-cancer doctor relationship, and according to recent findings, many doctors aren't quite living up to their end.

Researchers at the Fred Hutchinson Cancer Research Center and the Dana-Farber Cancer Institute examined the first consultations for 236 patients and 40 physicians in the so-called HEMA-COMM study looking for certain communication behaviors that experts believe ought to be part of the doctor-patient relationship from the get-go.

These patients came in to see a subspecialist with a range of diagnoses, with the slim majority (31%) having lymphoma. Median duration of the consultation was 80 minutes.

The frequency at which recommended communication behaviors occurred:
Discussion about purpose of the visit (78%)
Patient prior knowledge about disease (89%)
Patient preference for decision-making role (37%)
Patient understanding of presented information (31%)
Patient preference for information (5%)

Perhaps the most troubling figure is how often (23%) doctors hedged the prognosis, meaning that they would suggest that a prognostic estimate didn't apply to the individual. For example, the doctor might say that the patient's statistical prognosis gives them a 20% chance of responding to treatment, then hedge—or subvert—that bad news with something more reassuring, such as "I've had better results with my patients than what is published," or "Of course, let me preface this with you that numbers are meaningless in your situation."

However, most consultations (64%) featured unambiguous discussion of mortality risk without any hedging, and when surveyed afterwords, the overwhelming majority (98%) of patients were pleased with their involvement in decision-making, and four of five said they would recommend the doctor to another patient.

By Ross Bonander

Source: Lee S, et al "Content of hematologic malignancies consultations: Good and bad news from the HEMA-COMM Study" ASH Abstract 68.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap